Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 19/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 16/20 | 0.55 |
| ▸ | CCNA1 | P78396 | 16/20 | 0.55 |
| ▸ | CDK9 | P50750 | 3/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5867649 | 0.84 | CCNA2 (0.59) | CDK2CCNA2CCNA1 | |
| SCHEMBL5867732 | 0.84 | CCNA2 (0.62) | CDK2CCNA2CCNA1 | |
| SCHEMBL3567395 | 0.82 | CDK2 (0.53) | CDK2CCNA2CCNA1CDK9CDK5 | |
| SCHEMBL3564951 | 0.81 | CDK2 (0.47) | CDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL30458326 | 0.79 | CDK2 (0.61) | CDK2CCNA2CCNA1CDK9CDK5 | |
| SCHEMBL17632446 | 0.78 | USP30 (0.54) | CDK2CCNA2CCNA1 | |
| SCHEMBL17632448 | 0.78 | USP30 (0.54) | CDK2CCNA2CCNA1 | |
| SCHEMBL25941301 | 0.78 | CDK2 (0.67) | CDK2CCNE1 | |
| SCHEMBL25938137 | 0.78 | CDK2 (0.67) | CDK2CCNE1 | |
| SCHEMBL3559850 | 0.77 | NPY5R (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671072-B2 | Aminopyrazole derivatives as GSK-3 inhibitors | PFIZER INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | BENBOW JOHN W | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | GSK3B, GSK3A, GSKIP | CDK2 58/4885CCNA2 784/4885CCNA1 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.